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Abstract
Background: Several different strategies have been reported for the treatment of chondromyxoid fibromas, all with
variable outcomes and high recurrence rates.
Methods: We report on 22 consecutive cases of chondromyxoid fibromas treated by intralesional curettage, four of
which had adjuvant cementation at our institution between 2003 and 2010. We assessed the functional outcome
using the Musculoskeletal Tumour Society (MSTS) scoring system.
Results: Nine males and 16 females with a mean age of 36.5 years (range 11 to 73) and a mean follow-up of
60.7 months were included in the study. Local recurrence occurred in two patients (9%) within the first 2 years
following the index procedure. This was treated by re-curettage only of the residual defect. Two postoperative
complications occurred: a superficial wound infection in one patient and a transient deep peroneal nerve
neurapraxia in the other. The mean postoperative MSTS score was 96.7%.
Conclusions: Intralesional curettage and cementation is as an effective treatment strategy for chondromyxoid
fibromas, providing satisfactory functional results with a low recurrence rate. Careful case selection with stringent
clinical and radiographic follow-up is recommended.
Keywords: Chondromyxoid fibroma, Curettage, Cementation, Functional outcome, Case series, Management,
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Background
Chondromyxoid fibroma (CMF) is a rare, benign bone
tumour. It is associated with high local recurrence rates
with a small risk (<2%) of malignant transformation
[1-3]. It was first described in 1948 [4] and constitutes
about 1 to 2% of all bone tumours [3]. The tumour is
thought to originate from the physeal cartilage plate,
given the similar histological findings to chondroblas-
toma and the reported common involvement of both the
epiphysis and metaphysis [5,6]. CMF can frequently be
misdiagnosed histologically as a malignant lesion, due to
the finding of atypical pleomorphic hyperchromatic nu-
clei; however, mitoses are a rarity [5]. The tibia is the
most frequently involved bone with other affected sites
including the flat bones, facial bones, and bones of the
hand and foot [3,7,8].
The mean age at diagnosis is approximately 30 years,
but the lesion has a wide age distribution [1-3,9]. CMF
development is more aggressive in younger patients and
carries a slightly higher predilection for males than fe-
males [6]. The age of diagnosis was proposed as a factor
for increased recurrence rates, with the suggestion that
the reduced resistance of the paediatric thin cortices and
spongiosa contributes to the aggressive behaviour of the
lesion [6]. Furthermore, there is an increased recurrence
in patients less than 15 years of age, with the tumours
demonstrating myxoid tissue dominance [10]. In con-
trast, however, it has been reported that there is no dif-
ference in rate of recurrence and age of diagnosis, nor
was there any correlation between histological features
and increased tendency to recur [6,11]. Factors proposed
in its aetiology include chromosomal abnormalities and
immunological factors [12].
The differential diagnosis of CMF includes chon-
drosarcoma, chondroblastoma, fibrous dysplasia, non-
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cyst and simple bone cysts [3,13-15]. The potential for
misdiagnosis may occur in elderly patients, or in cases
in which lesions are found in unexpected sites [16].
Historically, wide excision or en-bloc segmental resec-
tion was recommended, with a reported recurrence rate
of 4% [11]. Curettage alone, without adjunctive treat-
ment such as cement, liquid nitrogen and phenol, is re-
ported to result in high recurrence rates (between 20
and 80%) [4,10,11]. However, Schajowicz and Gallardo
[11] reported no recurrence with combined curettage
and bone-grafting, whilst Gherlinzoni and colleagues [6]
demonstrated a rate of recurrence of 7%.
At present, there appears to be no agreed treatment
pathway for CMF. This is due to a number of factors,
and most likely due to the rarity of this tumour and dif-
ficulty in obtaining significant population data. We
present a cohort of 22 patients treated in our centre with
a standardised treatment approach (Figure 1). Previous
studies provide data from a number of treatment modal-
ities, but have relatively small patient numbers and
short-term follow-up. In view of the current literature,
there is much need for review of the treatment for CMF.
We reviewed our experience of patients with this rare
condition and evaluated our outcomes of intralesional
curettage and cementation as a treatment strategy.
Radiology
Characteristically, CMF is a sharply defined, eccentric,
round or oval geographic (less common) lytic lesion
centred in the metaphysis, which measures less than
5 cm at its greatest diameter in most cases. The appear-
ance of CMF in long bones is usually eccentric (Figure 2);
however, centrally placed lesions are more common in
thin bones (ribs, fibulae, and small tubular bones). The
edges are normally scalloped and the endosteal margin is
usually well demarcated by a rim of host bone sclerosis
(type A margin). Cortical thinning and/or replacement
(“expansion”) is quite frequent along with a trabeculated
appearance that largely results from ridging of the inner
border that surrounds host bone [2,3,12,15,17,18].
Pathological fractures rarely occur, with predisposing
factors including matrix or intralesional calcification and
periosteal new bone production [11,15]. In our series, we
did not encounter any patients presenting with patho-
logical fractures. Current literature suggests that periosteal
reaction, in most cases, is as a result of pathologic frac-
tures and is not usually present in CMF [1].
Plain radiographs alone are not sufficient for making a
diagnosis of CMF. We routinely perform computed tom-
ography (CT) and magnetic resonance imaging (MRI) in
all of our patients. Typical appearances can differ between
these radiological modalities with each investigation pro-
viding further diagnostic information (Table 1) [3,19,20].
Histology
The histology of CMF is usually typical, as shown by the
Mayo Clinic series [3]. It is a lobulated tumour com-
posed of stellate and spindle cells with variable cellular-
ity, usually more cellular at the periphery of the lobules.
The matrix is myxoid and in some cases contains coarse
calcification (Figure 3).
The differential diagnosis of CMF includes chondro-
sarcoma, CMF-like osteosarcomas and chondroblasto-
mas on histology.
Methods
A search of our regional bone tumour unit database was
used to identify patients diagnosed with CMF. Clinical
data were collected from the case notes, histology reports,
imaging studies, clinic reviews and patient questionnaires.
Patients were excluded if the lesion required wide excision
or amputation and if they had less than 1 year follow-up.
Between 2003 and 2010, 22 consecutive patients were
identified with histologically verified CMF who underwent
intralesional curettage and cementation of their lesion at
our institution. Patients who received bone grafting, shark
Referral
Multi-
disciplinary 
meeting
Imaging 
(XR, CT & MRI)
CT guided 
biopsy
Clinical 
evaluation
Histological 
diagnosis
Radiological 
diagnosis
CHONDROMYXOID 
FIBROMA 
(confirmed diagnosis)
Simple Curettage*
Re-discussion of 
case at MDT
* Intra-operative decision 
for cementation, based on 
size of residual defect
Figure 1 Algorithm of the standardised approach to treatment
of chondromyxoid fibromas at our institution. CT, computed
tomography; MDT, multi-disciplinary team; MRI, magnetic resonance
imaging; XR, plain radiographs.
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study due to small numbers.
There were nine males (40.9%) and 13 females (59.1%),
with a mean age of 30.6 years (range 11 to 73 years). The
mean overall follow-up was 60.7 months (range 8 to
110 months). Ten of the treated lesions occurred in the
tibia, four involved the metatarsals, three the calcaneum,
three the fibula, one the humerus and one the femur
(Table 2).
Patients were referred to our regional tumour centre and
managed by a multidisciplinary team. All patients had per-
sistent pain as the main presenting feature. Interestingly,
three patients (13.6%) developed pain after falling. Pre-
operative imaging included plain radiographs, CT and
MRI. Imaging studies were evaluated by musculoskeletal
consultant radiologists for focal bone lesions with geo-
graphic bone destruction, a sclerotic rim, lobulated mar-
gins, and septation [21].
After planning, patients underwent CT-guided needle
biopsy using a Jamsheedi needle and histology specimens
were obtained in all cases. The diagnosis of CMF was
reached combining radiological, histological (confirmed
on needle biopsy) and clinical findings in a multi-
disciplinary meeting. The patients included in this study
Figure 2 Radiographs showing CMF of the tibia with postoperative appearances following curettage and cementoma. (a) Anterior-posterior
radiograph of the left knee showing a lytic lesion (arrow) in the medial tibial plateau with a thin, partially sclerotic margin and very mild bone
expansion. There is no appreciable matrix mineralisation, and the articular surface of the knee joint is well-preserved. (b) Anterior-posterior
radiograph of the left knee following curettage and cementation (arrow), showing satisfactory post-operative appearance.
Table 1 Typical radiological features of chondromyxoid fibromas as seen on plain radiographs, computed tomography
and magnetic resonance imaging
Radiograph [20] Computed tomography [15] Magnetic resonance imaging [19]
Long bones: In addition to plain film features:
￿ Radiolucent ￿ Calcification may be visible ￿ Low signal intensity on T1-weighted images
￿ Lesions may be large ￿ Septations may be visible ￿ High signal intensity on T2-weighted images
￿ May be expansile
￿ Lobulated ￿ Heterogenous enhancement (Gadolinium)
￿ Geographic lesion with a sclerotic rim
Small bones (e.g. feet):
￿ Osteolytic with “scalloped” bone erosions
￿ Bone expansion
￿ Coarse trabeculation
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cortical window, followed by washout with saline pulsatile
lavage. Four out of the 22 patients (18.2%) required ad-
juvant treatment with bone cement to fill the resultant
intraosseous defects. This decision was taken intra-
operatively as the size of the residual defect may have
resulted in future fractures.
Patients were followed up at regular intervals of
6 months in the first year postoperatively and on an an-
nual basis thereafter for a minimum of 2 years. Plain ra-
diographs were obtained of the operated site at each
visit to identify local recurrence. Clinical outcome as-
sessment was performed using the Musculoskeletal
Tumour Society (MSTS) scoring system for both upper
and lower limbs [21].
The MSTS scoring system is a clinician-completed
system assigning numerical values (0–5) for six
categories - in the upper limb: pain, function, emotional
acceptance, hand positioning, dexterity, and lifting abil-
ity; in the lower limb: pain, function, emotional accept-
ance, ambulatory support, walking ability, and gait. A
numerical score and percentage rating was calculated for
comparison of our results.
Results
Function
The average MSTS score achieved in all 22 patients was
96.7%. The mean upper limb score was 97% in one pa-
tient (29/30) whereas the mean lower limb score in 21
patients was 96.3% (range 53 to 100%). All patients were
able to perform activities relating to their daily living
and occupation. None of the patients had pathological
fractures. One patient required long-term analgesia
other than that necessary during the postoperative re-
covery period. This patient had sustained multiple trau-
matic injuries from a previous road traffic accident and
was mobilised pre-operatively with the aid of two
crutches. This patient accounted for our lowest MSTS
score (15/30).
Complications
Postoperative complications occurred in only two pa-
tients (9.1%), with both cases being classified as early
complications. One of the patients developed a superfi-
cial wound infection, which resolved with a 7-day course
a.
c. b.
Figure 3 Histological appearance of typical chondromyxoid fibroma. (a) Low-power view shows distinct lobulation of the tumour with
intervening cellular stromal areas (2× magnification; haematoxylin and eosin stain). (b) Medium (10×) and (c) high (20×) magnification shows
stellate and spindle-shaped cell set in a chondroid matrix (haematoxylin and eosin stain).
Table 2 Summary of the site and distribution of
chondromyxoid fibromas in our patient cohort
Site Cases (n)
Tibia 10
Metatarsal 4
Calcaneum 3
Fibula 3
Humerus 1
Femur 1
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peroneal nerve neurapraxia with sensory loss after
curettage of the first metatarsal which recovered fully.
Oncological outcome
Local recurrence occurred in three patients (13.6%).
Two patients had adequate margins taken at the primary
procedure. Recurrence occurred within 6 months in
both cases. Treatment was re-curettage in both cases,
with no further recurrence to date.
We report one further case of recurrence. In this par-
ticular case, recurrence occurred 18 years after primary
curettage for CMF. This patient was referred to our unit
for further management and re-curettage of the lesion
was performed. We were unable to retrieve the initial
histology results to ascertain whether inadequate mar-
gins were taken at primary surgery.
Discussion
Current literature data suggest recurrence rates of 3 to
22%. The higher rates are associated with curettage
alone; improved results are reported with the use of ce-
mentation with or without bone-grafting [4,5,8,11,16].
We report a recurrence rate of 9.1% in our study. Our
results are in keeping with published literature but, more
importantly, demonstrate a low recurrence rate with
intralesional curettage and cementation. As already de-
scribed, four out of the 22 cases included in this study
received adjuvant cementation. This may have contrib-
uted to the low recurrence rate reported in this study, as
cement not only provides biomechanical stability but
also destroys any residual tumourous cells by thermal in-
jury. We acknowledge that this technique was not stan-
dardised in our cohort of patients and is therefore a
limitation of the study. Nevertheless, we feel that this
was an important step taken intra-operatively to avoid
the possible risk of complications. Cementation was to
fill the residual intraosseous defect and primarily pro-
vides biomechanical stability; however, our experience in
treating these tumours suggests that curettage alone is
sufficient for the majority of CMF tumours.
The rate of recurrence has been suggested to correlate
with age at diagnosis, with younger patients more likely
to have recurrences, which may be multiple [4,5,8,11,16],
although reports remain conflicting with regard to this
relationship. Due to the relatively low rate of recurrence
in our study, it is difficult to verify whether there is in
fact an argument to support these claims. Recurrences
reported from the two cases in this study demonstrate
no sex predilection (50:50 male:female), but do suggest
that recurrence occurs in younger patients; with a mean
age at recurrence of 19.5 years (range 18 to 23 years).
Some cases of recurrence are reported in the literature
to occur as late as 19 years from the original diagnosis
[3]. We support this statement with a recurrence seen in
our patient population at 18 years following primary
curettage. One theory postulates that this may be due to
the presence of tumorous microlobules deep in bony
crevices that can prove difficult to remove by curettage
[16]. Malignant transformation is rare, with reported
figures suggesting a 1 to 2% risk [16,21], similar to other
benign bone tumours. None of the cases in our series
underwent malignant transformation, as confirmed on
histological curettage analysis from intra-operative speci-
mens. Of two cases of CMF malignant transformation
reported in the recent literature [3], one proceeded to
malignant fibrous histiocytoma and the other to fibrosar-
coma. The latter had previously undergone radiotherapy.
The lack of typical diagnostic features in every case and
the propensity for recurrence may lead to misdiagnosis
of a malignant tumour. Hence, any lesion labelled as
CMF is best confirmed and managed in a specialist bone
centre.
Our study demonstrated excellent functional results
following intralesional curettage (82%) and cementation
(18%) of CMF. The lowest score in our series was sec-
ondary to other injuries that the patient sustained, unre-
lated to the surgery. Our recurrence rate was 9%, which
is slightly higher than that reported for curettage and
bone-grafting; however, it was better than previous studies
that performed curettage alone [8,11]. In cases where we
required cementation in addition to curettage, recon-
struction with polymethylmethacrylate bone cement
provided immediate stability, avoided the morbidity of
autogenous bone graft, and aided the postoperative radio-
graphic evaluation for signs of local recurrence [22].
Conclusion
In conclusion, CMF is a rare condition with few cases
reported in the literature, causing some debate regarding
optimal management. Whilst wide excision and en-bloc
excision procedures report the lowest rate of recurrence,
this results in subsequent functional deficit as well as
cosmestic concerns. Curettage alone has been reported
as showing relatively high rates of recurrence of up to
80%, with an improvement if this is combined with
bone-grafting of the defect. This study supports the view
that intralesional curettage is an effective treatment
strategy for the majority of CMF of long bones with oc-
casional adjuvant cementation being necessary to large
intraosseous defects that could result in future recur-
rence, instability and fracture. We report excellent over-
all functional results and propose that this treatment
option is a safe, minimally invasive procedure that pre-
serves function, has low morbidity, is cost effective, and
does not appear to have an adverse effect on long-term
outcome. Careful patient selection with stringent clinical
and radiographic follow-up is crucial for the successful
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without cementation as a surgical treatment in a special-
ist tumour centre.
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